AI-Driven Platform iLoF combines advanced AI and photonics to accelerate personalized drug discovery and development, presenting an opportunity to offer high-value AI integration, data analytics tooling, and biomarker data management services to pharmaceutical clients seeking faster R&D cycles.

Digital Biomarker Library With a digital library of biomarkers and biological profiles, iLoF could partner to provide standardized biomarker datasets, validation studies, and companion diagnostic support for clinical trials and targeted therapies.

Funding & Growth Recent funding rounds and headcount growth signal momentum and capability to scale collaborations; potential to propose co-development programs, joint ventures, or funded research projects with larger pharma and biotech customers.

Porto & Oxford Ties Strategic proximity to Oxford University and strong regional funding (ERDF) create openings for academic-industry collaborations, pilot programs, and access to talent for joint research initiatives in AI, photonics, and biotech.

Clinical Trial Acceleration ERDF-backed grants aimed at reducing patient recruitment time align with needs of CROs and pharma companies; propose solutions around faster patient screening, non-invasive testing, and digital recruitment support to shorten trial timelines.